Prellis Biologics
PrivateLast Round
Series C
Aug 10, 2022
Total Funding Raised
$64.55M
Company Overview
Prellis Biologics is a biotechnology company that specializes in advanced bioprinting technology to engineer human tissues in vitro, enabling precise reproduction of the human immune response for applications such as antibody discovery and tumor-immune modeling.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, 3D Printing, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prellis Biologics Comparables
Compare Prellis Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera Biologics Inc. | 80% | |
| Adimab | 76% | |
| Aspect Biosystems | 76% | |
Prellis Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 10, 2022 | ||||
| Series B | Dec 14, 2021 | ||||
| Series A Extension | May 19, 2020 | ||||
| Series A | Jul 29, 2019 | ||||
| Seed | Sep 14, 2017 | ||||
Accelerator | May 31, 2017 |
Key People
Founding team and executive leadership
Prellis Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series A Extension |
| 415 Ventures | Seed |
| Khosla Ventures | Series C, Series A Extension, Series A, Series B |
| WRVI Capital | Series C, Series B |
| Avidity Partners | Series C |
| Celesta Capital | Series C, Series B |
| IndieBio | Series A Extension, Series A, Seed, Series B, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 24, 2026
Developing programs in obesity, inflammation/immunology, and oncology.
- Oct 13, 2025
Proprietary 3D printed lymph node organoid technology named 'EXIS platform'.
Prellis Biologics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Prellis Biologics's valuation, stock price, and market status.